Cardiovascular effects of methamphetamine in Parkinson's disease patients

Nicola Pavese; Ornella Rimoldi; Alexander Gerhard; David J. Brooks; Paola Piccini

doi:10.1002/mds.10651

Cardiovascular effects of methamphetamine in Parkinson's disease patients

Nicola Pavese, Ornella Rimoldi, Alexander Gerhard, David J. Brooks, Paola Piccini

Research output: Contribution to journal › Article › peer-review

Abstract

Cardiovascular responses after intravenous methamphetamine were assessed in 11 Parkinson's disease (PD) patients. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and electrocardiogram (ECG) were monitored for 103 minutes. After methamphetamine administration, SBP and DBP increased significantly in both PD and normal controls whereas placebo had no effect. In PD patients, however, the duration of SBP and DBP responses to methamphetamine and the maximum increase from baseline was attenuated compared with the controls. A significant correlation was found between individual BP responsiveness and the Unified Parkinson's Disease Rating Scale (UPDRS) motor score. These findings suggest that in PD there is impairment of catecholamine release from peripheral sympathetic presynaptic terminals, which correlates with motor impairment. © 2003 Movement Disorder Society.

Original language	English
Pages (from-to)	298-303
Number of pages	5
Journal	Movement Disorders
Volume	19
Issue number	3
DOIs	https://doi.org/10.1002/mds.10651
Publication status	Published - Mar 2004

Keywords

Blood pressure
Methamphetamine
Parkinson's disease
Postganglionic sympathetic neurons

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/mds.10651

Cite this

@article{338173743cc94eeabd1d74a25c7de2ad,

title = "Cardiovascular effects of methamphetamine in Parkinson's disease patients",

abstract = "Cardiovascular responses after intravenous methamphetamine were assessed in 11 Parkinson's disease (PD) patients. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and electrocardiogram (ECG) were monitored for 103 minutes. After methamphetamine administration, SBP and DBP increased significantly in both PD and normal controls whereas placebo had no effect. In PD patients, however, the duration of SBP and DBP responses to methamphetamine and the maximum increase from baseline was attenuated compared with the controls. A significant correlation was found between individual BP responsiveness and the Unified Parkinson's Disease Rating Scale (UPDRS) motor score. These findings suggest that in PD there is impairment of catecholamine release from peripheral sympathetic presynaptic terminals, which correlates with motor impairment. {\textcopyright} 2003 Movement Disorder Society.",

keywords = "Blood pressure, Methamphetamine, Parkinson's disease, Postganglionic sympathetic neurons",

author = "Nicola Pavese and Ornella Rimoldi and Alexander Gerhard and Brooks, {David J.} and Paola Piccini",

year = "2004",

month = mar,

doi = "10.1002/mds.10651",

language = "English",

volume = "19",

pages = "298--303",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley & Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Cardiovascular effects of methamphetamine in Parkinson's disease patients

AU - Pavese, Nicola

AU - Rimoldi, Ornella

AU - Gerhard, Alexander

AU - Brooks, David J.

AU - Piccini, Paola

PY - 2004/3

Y1 - 2004/3

N2 - Cardiovascular responses after intravenous methamphetamine were assessed in 11 Parkinson's disease (PD) patients. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and electrocardiogram (ECG) were monitored for 103 minutes. After methamphetamine administration, SBP and DBP increased significantly in both PD and normal controls whereas placebo had no effect. In PD patients, however, the duration of SBP and DBP responses to methamphetamine and the maximum increase from baseline was attenuated compared with the controls. A significant correlation was found between individual BP responsiveness and the Unified Parkinson's Disease Rating Scale (UPDRS) motor score. These findings suggest that in PD there is impairment of catecholamine release from peripheral sympathetic presynaptic terminals, which correlates with motor impairment. © 2003 Movement Disorder Society.

AB - Cardiovascular responses after intravenous methamphetamine were assessed in 11 Parkinson's disease (PD) patients. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and electrocardiogram (ECG) were monitored for 103 minutes. After methamphetamine administration, SBP and DBP increased significantly in both PD and normal controls whereas placebo had no effect. In PD patients, however, the duration of SBP and DBP responses to methamphetamine and the maximum increase from baseline was attenuated compared with the controls. A significant correlation was found between individual BP responsiveness and the Unified Parkinson's Disease Rating Scale (UPDRS) motor score. These findings suggest that in PD there is impairment of catecholamine release from peripheral sympathetic presynaptic terminals, which correlates with motor impairment. © 2003 Movement Disorder Society.

KW - Blood pressure

KW - Methamphetamine

KW - Parkinson's disease

KW - Postganglionic sympathetic neurons

U2 - 10.1002/mds.10651

DO - 10.1002/mds.10651

M3 - Article

SN - 0885-3185

VL - 19

SP - 298

EP - 303

JO - Movement Disorders

JF - Movement Disorders

IS - 3

ER -

Cardiovascular effects of methamphetamine in Parkinson's disease patients

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this